Home  /  Resource Library  /  Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

Results of a study investigating venetoclax, obinutuzumab and bendamustine for treatment of CLL.